Monarch Networth Capital’s Institutional equity desk has released an initiating coverage video report on Alembic Pharmaceuticals with a BUY and TP of INR 750, the highest within consensus. Alembic’s US business will be driven by faster monetization of the current product pipeline owing to an easing pricing environment and continuing momentum of Sartans. Further, investments of INR ~26bn over last four years across R&D and manufacturing will likely show results in the US market. It’s secret sauce remains its ability to scale with judicious capital allocation and execution prowess to capitalize on shortages and limited competition products. Moreover, domestic business, presently undergoing a strategic reset, should revert to industry growth. Improving business profile and strong earnings visibility make ALPM worthy of re-rating. To view our complete report and investment rationale,
kindly click -
To know more, please contact our analyst: vinit.gala@mnclgroup.com
Regards,
Vinit Gala
Analyst
Monarch Networth Capital
0 Comments